TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32762056

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 32762394

Group type: EXPERIMENTAL
Intervention: Valproic acid treatment
Number of subjects: 260
Study: 32762457

Group type: EXPERIMENTAL
Intervention: Virtual visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 0
Study: 32762458

Group type: EXPERIMENTAL
Intervention: GlycA (375 μmol/L mean)
Number of subjects: 6507

Group type: EXPERIMENTAL
Intervention: GlycA (highest quartile)
Number of subjects: 6507
Study: 32762644

Group type: EXPERIMENTAL
Intervention: Stand When You Can (SWYC) intervention
Number of subjects: 10
Study: 32762662

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) combined with external beam radiotherapy (EBRT)
Number of subjects: 125
Study: 32762706

Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-pressure respiratory support (PEEP ≥6 cm H2O)
Number of subjects: 5
Study: 32762980

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32763071

Group type: EXPERIMENTAL
Intervention: Moderate or severe LVOT calcification
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Balloon-expandable valves with moderate or severe LVOT calcification
Number of subjects: 1635
Study: 32763073

Group type: EXPERIMENTAL
Intervention: Repositioned group (Evolut R or PRO valve with repositioning)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Nonrepositioned group (Evolut R or PRO valve without repositioning)
Number of subjects: 946
Study: 32763152

Group type: EXPERIMENTAL
Intervention: Universal test-and-treat (UTT) intervention
Number of subjects: 975
Study: 32763431

Group type: EXPERIMENTAL
Intervention: Micra implantation in precluded patients
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Micra implantation in nonprecluded patients
Number of subjects: 546

Group type: COMPARATOR
Intervention: Single-chamber TV-PPM
Number of subjects: 546
Study: 32763874

Group type: EXPERIMENTAL
Intervention: Healthy children and adolescents (PEF and FEV1 variability assessment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Children and adolescents with asthma (PEF and FEV1 variability assessment)
Number of subjects: 200
Study: 32763882

Group type: EXPERIMENTAL
Intervention: Point-of-care HIV-1 RNA testing combined with standard rapid antibody tests; 12 months follow-up for clinical outcomes.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Assisted HIV partner notification services; 12 months follow-up for clinical outcomes.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Intervention period; follow-up for viral suppression by month 6 and month 12 following ART initiation.
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Observation period; standard care without the intervention.
Number of subjects: 1500
Study: 32763967

Group type: EXPERIMENTAL
Intervention: Computational simulation arm (experimental)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment arm (control)
Number of subjects: 200
Study: 32764098

Group type: EXPERIMENTAL
Intervention: Timed motor function measures
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Genotype
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: c.826C>A mutation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 10-meter walk/run
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Motor function in adults
Number of subjects: 69
Study: 32764775

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (> 100 up to 325 mg daily)
Number of subjects: 69911

Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 69911

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 69911

Group type: COMPARATOR
Intervention: Low-dose aspirin (≤ 100 mg daily)
Number of subjects: 69911

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 69911

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 69911

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 69911
Study: 32764908

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0

Group type: COMPARATOR
Intervention: BUD/FOR
Number of subjects: 0
Study: 32765053

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (3 mL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT; IV paracetamol 1 g or ketoprofen 100 mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT)
Number of subjects: 69
Study: 32765052

Group type: EXPERIMENTAL
Intervention: PECSII block with 30mL of bupivacaine 0.25%
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB) with 30mL of bupivacaine 0.25%
Number of subjects: 180

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 180
Study: 32765056

Group type: EXPERIMENTAL
Intervention: Mirogabalin (7.5 mg twice daily for moderate renal impairment; 7.5 mg once daily for severe renal impairment)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 35
Study: 32765156

Group type: EXPERIMENTAL
Intervention: Subspecialist treatment for severe asthma
Number of subjects: 936
Study: 32765189

Group type: EXPERIMENTAL
Intervention: New perioperative practice model (NPPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard perioperative care (control)
Number of subjects: 0
Study: 32766181

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study: 32766383

Group type: EXPERIMENTAL
Intervention: 5-day postexposure prophylaxis with oseltamivir
Number of subjects: 222

Group type: COMPARATOR
Intervention: 10-day postexposure prophylaxis with oseltamivir
Number of subjects: 222
Study: 32766469

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of nerve growth factor (NGF) into the right masseter muscle on days 0 and 2.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pain diaries completed twice daily from day 0 to day 30.
Number of subjects: 150
Study: 32766725

Group type: EXPERIMENTAL
Intervention: Single oral dose of ciprofloxacin 500 mg
Number of subjects: 106
Study: 32766875

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg on days 1 and 15 of a 28-day cycle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 21
Study: 32766882

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro CGM
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meals ranked by Abbott CGM
Number of subjects: 16

Group type: COMPARATOR
Intervention: Meals ranked by Dexcom CGM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Kendall rank correlation coefficient
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Missing glycemic reduction
Number of subjects: 16
Study: 32766885

Group type: EXPERIMENTAL
Intervention: Histidine supplementation at 12 g/d (Study 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Histidine supplementation at 16 g/d (Study 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Histidine supplementation (4, 8, and 12 g/d in Study 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Histidine supplementation (16 g/d in Study 2)
Number of subjects: 80
Study: 32766890

Group type: EXPERIMENTAL
Intervention: FTC/TDF (daily oral coformulated emtricitabine and tenofovir disoproxil fumarate)
Number of subjects: 48
Study: 32766944

Group type: EXPERIMENTAL
Intervention: Slow pathway (SP) ablation
Number of subjects: 45
Study: 32766953

Group type: EXPERIMENTAL
Intervention: Apixaban < 48 h (Early group)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Apixaban ≥ 48 h (Late group)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Early group
Number of subjects: 686
Study: 32766961

Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 25
Study: 32767054

Group type: EXPERIMENTAL
Intervention: NIRS monitoring during surgery
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SAGE scale assessment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Time required for NIRS data collection
Number of subjects: 49
Study: 32767153

Group type: EXPERIMENTAL
Intervention: Gut microbiome analysis in STC group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCFA concentration analysis in STC group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for Acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for Propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for gut microbiome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of Ruminococcus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of Roseburia
Number of subjects: 0
Study: 32767659

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) containing DNA (EV-DNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EV-DNA in clinical settings
Number of subjects: 0
Study: 32767997

Group type: EXPERIMENTAL
Intervention: APOE ε4
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Heart disease
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 1100
Study: 32768158

Group type: EXPERIMENTAL
Intervention: 66 Gy SIB-IMRT
Number of subjects: 9
Study: 32768179

Group type: EXPERIMENTAL
Intervention: Bleeding leading to a postoperative haemoglobin <70 g L
Number of subjects: 16079

Group type: EXPERIMENTAL
Intervention: Bleeding meeting predefined screening criteria
Number of subjects: 16079
Study: 32768540

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to the common peroneal nerve (geko™)
Number of subjects: 8
Study: 32769075

Group type: EXPERIMENTAL
Intervention: Videoconferencing and self-administered tests of functional mobility and strength
Number of subjects: 10

Group type: COMPARATOR
Intervention: Videoconference
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remote assessment test protocol
Number of subjects: 10
Study: 32769736

Group type: EXPERIMENTAL
Intervention: MINIject
Number of subjects: 31
Study: 32769752

Group type: EXPERIMENTAL
Intervention: IOLMaster 700 (biometer A)
Number of subjects: 209
Study: 32769773

Group type: EXPERIMENTAL
Intervention: Interventions to reduce risk of opioid overdose following discharge from the Emergency Department
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32769835

Group type: EXPERIMENTAL
Intervention: Preinjury psychiatric history
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: History of prior TBI
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Post-TBI symptoms (measured by Rivermead Post-Concussion Symptoms Questionnaire)
Number of subjects: 1158
Study: 32770263

Group type: EXPERIMENTAL
Intervention: CA6 rs17032907 gene variant
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CA6 rs17032907 gene variant (dominant model CC vs. TT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Genotype CC and allele C presence
Number of subjects: 200
Study: 32770443

Group type: EXPERIMENTAL
Intervention: One-on-one, virtual/online intervention delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional group-based format
Number of subjects: 0
Study: 32770466

Group type: EXPERIMENTAL
Intervention: Southern respondents
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Respondents who routinely tested patients prior to surgery
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Centers not fully dedicated to COVID-19 care
Number of subjects: 299
Study: 32770704

Group type: EXPERIMENTAL
Intervention: Placement of a rectal balloon catheter alongside the AAR catheter
Number of subjects: 35
Study: 32770720

Group type: EXPERIMENTAL
Intervention: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation; flat doses of 250 mg Q2W or 500 mg every four weeks (Q4W) in multihistology expansion cohort.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Budigalimab at various doses.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Budigalimab in both Japanese and Western patients.
Number of subjects: 59
Study: 32770845

Group type: EXPERIMENTAL
Intervention: Medication reconciliation conducted by a pharmacist
Number of subjects: 1884

Group type: EXPERIMENTAL
Intervention: Risk score based on identified risk factors
Number of subjects: 1884
Study: 32770946

Group type: EXPERIMENTAL
Intervention: GP empathy assessed using The Care Measure (CARE)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patient Enablement Instrument (PEI)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Health check consultation leading to lifestyle change
Number of subjects: 93
Study: 32770954

Group type: EXPERIMENTAL
Intervention: Direct sampling following a specific respiratory manoeuvre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect sampling during passive respiratory activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TB chemotherapy
Number of subjects: 0
Study: 32771020

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT) intervention, eighteen 1-h sessions
Number of subjects: 10
Study: 32771060

Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) derived from PET/MRI
Number of subjects: 90
Study: 32771088

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily for 4 weeks, followed by olaparib 300 mg twice daily and durvalumab 1.5 g intravenously every 4 weeks until disease progression.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Olaparib and durvalumab combination treatment.
Number of subjects: 34
Study: 32771575

Group type: EXPERIMENTAL
Intervention: Stress CMR with evidence of ischemia or late gadolinium enhancement (LGE)
Number of subjects: 582

Group type: COMPARATOR
Intervention: No CMR evidence of ischemia or LGE
Number of subjects: 582
Study: 32771685

Group type: EXPERIMENTAL
Intervention: Asthma Control Test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32771997

Group type: EXPERIMENTAL
Intervention: Portico device via subclavian/axillary access
Number of subjects: 45
Study: 32772073

Group type: EXPERIMENTAL
Intervention: 6% O2 group
Number of subjects: 1125

Group type: COMPARATOR
Intervention: 20% O2 group (atmospheric O2)
Number of subjects: 1125
Study: 32772323

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TTh) for 27.63 ± 3.64 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TTh)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated hypogonadal men (n=46)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Eugonadal men (n=17)
Number of subjects: 15
Study: 32772680

Group type: EXPERIMENTAL
Intervention: Ischemic stroke participants
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 86
Study: 32772769

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells therapy
Number of subjects: 17
Study: 32772863

Group type: EXPERIMENTAL
Intervention: French adaptation of the Family Relationship Index (FRI)
Number of subjects: 1657
Study: 32773243

Group type: EXPERIMENTAL
Intervention: CYD-TDV (live, attenuated, tetravalent dengue vaccine)
Number of subjects: 0
Study: 32773348

Group type: EXPERIMENTAL
Intervention: ADVANCE programming
Number of subjects: 3528

Group type: COMPARATOR
Intervention: No ADVANCE programming (control)
Number of subjects: 3528
Study: 32773366

Group type: EXPERIMENTAL
Intervention: Thrive by Three intervention
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1531
Study: 32773376

Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) employment intervention program
Number of subjects: 56
Study: 32773383

Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) intervention, specifically the iFOUR program adapted for youth, aimed at increasing job-seeking self-efficacy and career readiness.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: In-depth interviews and focus groups with YMSM, YTW, and GNC youth.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Brief interviews with LGBTQ-inclusive employers.
Number of subjects: 21
Study: 32773447

Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for Injection (DAXI) 40U, up to 3 treatments over a maximum of 84 weeks
Number of subjects: 2691
Study: 32773474

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir 800 mg once daily and etravirine 400 mg once daily or 200 mg twice daily
Number of subjects: 15
Study: 32773964

Group type: EXPERIMENTAL
Intervention: FoodImage smartphone app
Number of subjects: 24

Group type: COMPARATOR
Intervention: Weighed diaries
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visually estimated diaries
Number of subjects: 24
Study: 32774184

Group type: EXPERIMENTAL
Intervention: Invasive tools for quantifying microcirculatory function; specific dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive pressure measurements; specific dosage and duration not available.
Number of subjects: 0
Study: 32774419

Group type: EXPERIMENTAL
Intervention: Comprehensive Spa Therapy using Therapeutic Radon-Sulfur Waters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32774889

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (PT) including proprioceptive neuromuscular facilitation (PNF) techniques, endurance training, and individually indicated interventions (5 to 9 sessions over 3 to 4 weeks).
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG) with no specific intervention mentioned.
Number of subjects: 20
Study: 32775606

Group type: EXPERIMENTAL
Intervention: New ACOMI/non-ACOMI ECG approach
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Non-STEMI group
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Early intervention in patients with non-ACO-predicting ECGs
Number of subjects: 3000
Study: 32775822

Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 17
Study: 32775974

Group type: EXPERIMENTAL
Intervention: Breath samples from patients with NAFLD cirrhosis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination of dimethyl sulfide and D-limonene
Number of subjects: 43

Group type: COMPARATOR
Intervention: Breath samples from healthy volunteers
Number of subjects: 43
Study: 32775985

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Paricalcitol
Number of subjects: 44
Study: 32776135

Group type: EXPERIMENTAL
Intervention: ESBL-producing Klebsiella pneumoniae sequence type 101 isolated from clinical samples and food (poultry)
Number of subjects: 3
Study: 32776159

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride multilayer extended-release capsules (MPH-MLR) at doses of 10, 15, or 20 mg
Number of subjects: 10
Study: 32776309

Group type: EXPERIMENTAL
Intervention: COVID-19 positive mothers
Number of subjects: 125
Study: 32776402

Group type: EXPERIMENTAL
Intervention: Val/Val group from the rs6265, BDNF
Number of subjects: 218

Group type: COMPARATOR
Intervention: Met allele groups
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: BDNF rs6265
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Val/Val phenotype of BDNF
Number of subjects: 218
Study: 32776489

Group type: EXPERIMENTAL
Intervention: Episodic treatment (n=10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (n=14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard treatment (aPCC and/or rFVIIa)
Number of subjects: 24
Study: 32776632

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg daily and Sorafenib 200 mg twice daily
Number of subjects: 17
Study: 32776990

Group type: EXPERIMENTAL
Intervention: Lockdown situation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived stress and anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boredom and sadness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger and fear of death
Number of subjects: 0
Study: 32777064

Group type: EXPERIMENTAL
Intervention: Ixazomib (4 mg on days 1, 8, and 15 of a 28-day cycle, started on day +5)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 25
Study: 32777116

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d for 21 days in combination with idarubicin and cytarabine chemotherapy
Number of subjects: 33
Study: 32777335

Group type: EXPERIMENTAL
Intervention: 24 Gy single-dose radiation therapy (SDRT)
Number of subjects: 292
Study: 32778047

Group type: EXPERIMENTAL
Intervention: Non-invasive vascular unloading technique (Nexfin®)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semi-invasive pulse contour analysis reference method (FloTrac™)
Number of subjects: 60
Study: 32778059

Group type: EXPERIMENTAL
Intervention: My Tools 4 Care - In Care (MT4C-In Care)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 280
Study: 32778061

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted, contrast-enhanced MRI for detection of liver metastases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follow-up imaging with paired CT and MRI at 3-, 6-, and 12-months as an alternative reference standard
Number of subjects: 0